HCG (Human Chorionic Gonadotropin) — Indexed Studies

Spectrum of Colopathy and Severe Polyposis Associated with Pentosan Polysulfate Sodium Maculopathy: A Retrospective Case Series.

Feo A, Popovic MM, Faghihi S et al.

Effects of pentosan polysulfate sodium on synovial fluid biomarkers in moderate to severe knee osteoarthritis: an exploratory, phase 2, randomized, double-blind, placebo-controlled trial.

Skerrett DL, Stapledon CJM, Ahuja M et al.

Severe bilateral retinal degeneration following a twenty-six-year pentosan polysulfate sodium exposure: a case report.

Zhao AT, Wibbelsman TD, Calotti M et al.

Efficacy and safety of pentosan polysulfate therapy in patients with interstitial cystitis for relief of lower urinary tract symptoms: 15-year single center experience.

Song SH, Song B, Jung G et al.

Pigmentary Maculopathy in Patients with Interstitial Cystitis: Association with Pentosan Polysulfate and Other Therapies.

Qin S, Evans JK, Jeong C et al.

A single-center, phase 1/2a trial of hESC-derived mesenchymal stem cells (MR-MC-01) for safety and efficacy in interstitial cystitis patients.

Kyung YS, Hong KS, Chung HM et al.

Pentosan Polysulfate Sodium and Maculopathy in Patients with Interstitial Cystitis: A Systematic Review and Meta-Analysis.

Lee J, Kim YJ, Lee K et al.

Retrospective study of incidence/prevalence of pigmentary maculopathy and retinopathy in patients receiving pentosan polysulfate sodium.

Yuan Z, Vaughan S, Jeffcoat C et al.

Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial.

Siddiq MAB, Liu X, Fedorova T et al.

Open-label, single-center, clinical study evaluating the safety, tolerability and clinical effects of pentosan polysulfate sodium in subjects with mucopolysaccharidosis I.

Bratkovic D, Gravance C, Ketteridge D et al.

Efficacy of Pentosan Polysulfate Treatment in Patients with Interstitial Cystitis/Bladder Pain Syndrome.

Arıkan MG, Çakıroğlu B

Incidence and Risk of Retinopathy in Patients With and Without Interstitial Cystitis and Pentosan Polysulfate Sodium Use.

Desjarlais EB, Medic V, Kim JE

MACULAR HOLE IN A PATIENT WITH PENTOSAN POLYSULFATE MACULOPATHY.

Arora N, Hoyek S, Patel NA

REFINING THE RETINAL PHENOTYPE OF PATIENTS WITH SUSPECTED PENTOSAN POLYSULFATE SODIUM RETINOPATHY.

Kalaw FGP, Arias JD, Walker E et al.

The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study.

Liu X, Virk S, Fedorova T et al.

Characterization of pentosan polysulfate patients for development of an alert and screening system for ophthalmic monitoring.

Hom GL, Kuo BL, Ross JH et al.

Two-Year Outcomes After Variable Duration of Drug Cessation in Patients With Maculopathy Associated With Pentosan Polysulfate Use.

Jung EH, Lindeke-Myers A, Jain N

Pentosan Polysulfate-Associated Dysplasia in Patients With Inflammatory Bowel Disease: A Case Series.

Anderson J, Frost S, Keyashian K et al.

Type 3 macular neovascularization in a patient with pentosan polysulfate maculopathy.

Bousquet E, Lee BA, Santina A et al.

A post-trial follow-up study of pentosan polysulfate monotherapy on preventing recurrent urinary tract infection in women.

Lee YJ, Chang SJ, Lin HY et al.

Role of oral pentosan polysulfate in Bacillus Calmette-Guérin therapy in patients with non-muscle-invasive bladder cancer.

Lee HY, Jung SI, Lim DG et al.

Pentosan polysulfate regulates hepcidin expression in native Mongolian horses.

Wijekoon S, Tsogbadrakh M, Sunaga T et al.

Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis with Hunner's lesions or glomerulations: systematic review and meta-analysis.

Grigoryan B, Kasyan G, Pivazyan L et al.

Macular Findings of Patients on Pentosan Polysulfate Sodium.

Blackorby BL, Banda H, Smith BT et al.

Case Report: Pentosan Polysulfate Sodium Maculopathy Originally Diagnosed as Pattern Macular Dystrophy.

Case AW, Anderson MJ, Sayomac LE

Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study.

Krishnan R, Duiker M, Rudd PA et al.

Identification of Patients with Pentosan Polysulfate Sodium-Associated Maculopathy through Screening of the Electronic Medical Record at an Academic Center.

Higgins K, Welch RJ, Bacorn C et al.

Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation.

Shah R, Simonett JM, Lyons RJ et al.

Retinal Toxicity in a Patient on Pentosan Polysulfate Sodium.

Wingelaar MJ, Raevis JJ, Conlin KA et al.

Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States.

Ludwig CA, Vail D, Callaway NF et al.

Safety Study of Sodium Pentosan Polysulfate for Adult Patients with Mucopolysaccharidosis Type II.

Orii K, Lim A, Tomatsu S et al.

The efficacy of pentosan polysulfate monotherapy for preventing recurrent urinary tract infections in women: A multicenter open-label randomized controlled trial.

Tseng CS, Chang SJ, Meng E et al.

Pharmacologic control of oxidative stress and inflammation determines whether diabetic glomerulosclerosis progresses or decreases: A pilot study in sclerosis-prone mice.

Grosjean F, Yubero-Serrano EM, Zheng F et al.

Sodium pentosan polysulfate efficacy as thromboprophylaxis agent in high-risk women following gynecological surgery.

Indirayani I, Kalok A, Nik Ismail NA et al.

Improved clinical outcome measures of knee pain and function with concurrent resolution of subchondral Bone Marrow Edema Lesion and joint effusion in an osteoarthritic patient following Pentosan Polysulphate Sodium treatment: a case report.

Sampson MJ, Kabbani M, Krishnan R et al.

Role of oral pentosan polysulphate in the reduction of local side effects of BCG therapy in patients with non-muscle-invasive bladder cancer: a pilot study.

Yadav S, Tomar V, Yadav SS et al.

Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase II study.

Hennermann JB, Gökce S, Solyom A et al.

Efficacy of intravesical pentosan polysulfate sodium in cats with obstructive feline idiopathic cystitis.

Delille M, Fröhlich L, Müller RS et al.

Treatment of experimentally induced osteoarthritis in horses using an intravenous combination of sodium pentosan polysulfate, N-acetyl glucosamine, and sodium hyaluronan.

Koenig TJ, Dart AJ, McIlwraith CW et al.

Pentosan polysulfate treatment ameliorates motor function with increased serum soluble vascular cell adhesion molecule-1 in HTLV-1-associated neurologic disease.

Nakamura T, Satoh K, Fukuda T et al.

A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease.

Kutlar A, Ataga KI, McMahon L et al.

Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate.

Terada T, Tsuboi Y, Obi T et al.

Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases.

Tsuboi Y, Doh-Ura K, Yamada T

Evaluation of health-related quality of life in patients with painful bladder syndrome/interstitial cystitis and the impact of four treatments on it.

Sairanen J, Leppilahti M, Tammela TL et al.

Use of pentosan polysulphate in cats with idiopathic, non-obstructive lower urinary tract disease: a double-blind, randomised, placebo-controlled trial.

Wallius BM, Tidholm AE

Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus.

Laczy B, Cseh J, Mohás M et al.

Association between response to pentosan polysulfate sodium therapy for interstitial cystitis and patient questionnaire-based treatment satisfaction.

Sand PK, Kaufman DM, Evans RJ et al.

Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium.

Sairanen J, Hotakainen K, Tammela TL et al.

Late Development of Clinically Apparent Pentosan Polysulfate Maculopathy after Drug Cessation.

N'jai B, Rajagopalan A, Milner D et al.

Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis.

Stapledon CJM, Krishnan R, Peat RA et al.